OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Nuclear Medicine is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Effect of COVID-19 Lockdown on Oncologic Patients Undergoing Treatment at a Tertiary-Care Hospital in India	191
Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study	188
Practicing Medicine in Wartime Ukraine	173
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma	109
A Brief Report on the Results of the 2024 National Survey of Nuclear Medicine Conducted by the Chinese Society of Nuclear Medicine	105
Total-Body Parametric Imaging Using Relative Patlak Plot	104
¹⁷⁷Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial	103
Molecular Imaging of Pulmonary Fibrosis	103
Collagen Hybridizing Peptide–Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis	101
Reply: On Facilitating the End of the Linear No-Threshold Era	95
Molecular Imaging in Cancer Chemoresistance: What’s Brewing?	92
Positron Range Correction Helps Enhance the Image Quality of Cardiac⁸²Rb PET/CT	90
Letter to the Editor: “¹⁸F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study” [J Nucl Med 2022; 63:147–157]	88
Single-Domain Antibody Theranostics on the Horizon	84
Initial Results of⁶⁸Ga-FAPI-46 PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer	82
An¹⁸F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non–Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy	81
Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention	79
Challenges and Promise for Nuclear Medicine in Africa	78
Perspectives on Theranostics and Nuclear Medicine	76
Myocardial External Efficiency in Asymptomatic Severe Primary Mitral Regurgitation Using¹¹C-Acetate PET	70
PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma	68
¹¹C-PiB and¹²⁴I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention	67
Deep Learning–Enabled Quantification of^99mTc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis	64
A Life in Nuclear Medicine in Israel	62
Biokinetics and Dosimetry of [¹⁷⁷Lu]Lu-Pentixather	61

Advancing Nuclear Medicine in Australia over 3 Decades	61
Advancing Clinical Trial Innovation in Pancreatic Cancer	59
Reply: What Does an Imaging “Selection” Claim Actually Mean?	58
Longitudinal Tau PET Using¹⁸F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters	57
A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study	57
Total-Body PET System Designs with Axial and Transverse Gaps: A Study of Lesion Quantification and Detectability	55
From Scientist to Analyst to Strategist	53
PET/CT with Myocardial Blood Flow Assessment Is Prognostic of Cardiac Allograft Vasculopathy Progression and Clinical Outcomes	51
Borderline Findings inO-(2-[¹⁸F]-Fluoroethyl)-l-Tyrosine PET of Patients with Suspected Glioma Relapse: Role in Clinical Practice	51
Imaging Demyelinated Axons After Spinal Cord Injuries with PET Tracer [¹⁸F]3F4AP	50
Development of Fluorinated NP-59: A Revival of Cholesterol Use Imaging with PET	50
Validation of¹⁸F-rhPSMA-7 and¹⁸F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer	50
Repetitive Early⁶⁸Ga-FAPI PET Acquisition Comparing⁶⁸Ga-FAPI-02,⁶⁸Ga-FAPI-46, and⁶⁸Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Infla	48
Noninvasive Assessment of Acute Graft-Versus-Host Disease of the Gastrointestinal Tract After Allogeneic Hemopoietic Stem Cell Transplantation Using¹⁸F-FDG PET	48
Prostate Cancer Treatment:¹⁷⁷Lu-PSMA-617 Considerations, Concepts, and Limitations	48
Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls	47
Combined PARP1-Targeted Nuclear Contrast and Reflectance Contrast Enhance Confocal Microscopic Detection of Basal Cell Carcinoma	47
Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor PET in a Human-Sized Swine Model	46
Adding Nontumor Radiomic Features to the Prognostic Model Is Bothersome but Useful	45
c-MET Receptor–Targeted Fluorescence on the Road to Image-Guided Surgery in Penile Squamous Cell Carcinoma Patients	45
Preclinical Comparison of the⁶⁴Cu- and⁶⁸Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [⁶⁸Ga]Ga-AMTG PET/CT	45
Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen–Directed Radioligand Therapy	44
Diagnostic Accuracy of MR Spectroscopic Imaging and¹⁸F-FET PET for Identifying Glioma: A Biopsy-Controlled Hybrid PET/MRI Study	44
Hemodynamic Insights into Combined Fractional Flow Reserve and Instantaneous Wave-Free Ratio Assessment Through Quantitative [¹⁵O]H₂O PET Myocardial Perfusion Imaging	43
V/Q SPECT/CT in the Time of COVID-19: Changing the Order to Improve Safety Without Sacrificing Accuracy	43
Automated Motion Correction for Myocardial Blood Flow Measurements and Diagnostic Performance of⁸²Rb PET Myocardial Perfusion Imaging	43
A Life Study in Academic Leadership	43
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [¹⁵O]H₂O PET Imaging	43
MRI-Guided Motion-Corrected PET Image Reconstruction for Cardiac PET/MRI	43
Dynamic Human Brain Imaging with a Portable PET Camera: Comparison to a Standard Scanner	41
Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of¹⁸F-FDG PET/CT and Conventional CT Imaging	40
A Deep-Learning–Based Partial-Volume Correction Method for Quantitative¹⁷⁷Lu SPECT/CT Imaging	40
Unraveling the Hypocalcemic Response to¹⁷⁷Lu-Prostate-Specific Membrane Antigen Therapy	40
Precision of Myocardial Blood Flow and Flow Reserve Measurement During CZT SPECT Perfusion Imaging Processing: Intra- and Interobserver Variability	39
The Latest Advances in Imaging Crosstalk Between the Immune System and Fibrosis in Cardiovascular Disease	38
[¹⁸F]FDG and [⁶⁸Ga]Ga-FAPI-04–Directed Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms	38
Governments Are Constitutionally Permitted to Provide “Vaccine Passports”—Some May Also Be Constitutionally Obligated to Do So	38
Distinguishing Primary Lateral Sclerosis from Parkinsonian Syndromes with the Help of Advanced Imaging	38
Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with⁶⁸Ga-N188	37
Pioneering Research on Cancer Quality of Life and Outcomes	37
Oncologic Staging with⁶⁸Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than¹⁸F-FDG PET/CT	37
Dosimetric Variability Across a Library of Computational Tumor Phantoms	37
Looking at the Future of Prostate Cancer Treatment	36
Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice	36
Influence of Fc Modifications and IgG Subclass on Biodistribution of Humanized Antibodies Targeting L1CAM	35
Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden	35
Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities	34
Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer	34
Image-Guided High-Intensity Focused Ultrasound, A Novel Application for Interventional Nuclear Medicine?	34
Distinction of Lymphoma from Sarcoidosis on¹⁸F-FDG PET/CT: Evaluation of Radiomics-Feature–Guided Machine Learning Versus Human Reader Performance	33

A Pilot Study of⁶⁸Ga-PSMA11 and⁶⁸Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer	33
Debating the Future of Nuclear Medicine: The Greek Experience	32
Quantitative Accuracy Assessment of the NeuroEXPLORER for Diverse Imaging Applications: Moving Beyond Standard Evaluations	32
Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States	32
⁶⁸Ga-DOTATATE Prepared from Cyclotron-Produced⁶⁸Ga: An Integrated Solution from Cyclotron Vault to Safety Assessment and Diagnostic Efficacy in Neuroendocrine Cancer Patients	32
α-Synuclein PET and Parkinson Disease Therapeutic Trials: Ever the Twain Shall Meet?	32
The Future of Nuclear Medicine in the United States	32
[¹⁸F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [¹⁸F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status	32
Solving Challenging Puzzles	31
2024 SNMMI Highlights Lecture: General Clinical Specialties	31
Comparability of Quantifying Relative Lung Ventilation with Inhaled^99mTc-Technegas and¹³³Xe in Patients Undergoing Evaluation for Lung Transplantation	31
Imaging of the Aging Human Brain	30
In Vivo Visualization and Quantification of Neutrophil Elastase in Lungs of COVID-19 Patients: A First-in-Humans PET Study with¹¹C-NES	30
Localized In Vivo Prodrug Activation Using Radionuclides	30
Is Routine Dosimetry Really Happening?	30
Enhancing ²²³Ra Treatment Efficacy by Anti-β1 Integrin Targeting	30
Incidental Airway Findings on PET/CT with¹⁸F-PSMA	29
Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for⁸⁹Zr-Trastuzumab	29
Using Molecular Imaging to Enhance Decision Making in the Management of Pituitary Adenomas	28
A Multicenter Study on Observed Discrepancies Between Vendor-Stated and PET-Measured⁹⁰Y Activities for Both Glass and Resin Microsphere Devices	28
Effectiveness of²²⁵Ac-Labeled Anti-EGFR Radioimmunoconjugate in EGFR-Positive Kirsten Rat Sarcoma Viral Oncogene and BRAF Mutant Colorectal Cancer Models	28
Molecular Signature of ¹⁸F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study	28
Role of¹⁸F-FDG PET/CT in Large Vessel Vasculitis and Polymyalgia Rheumatica	27
Radioiodine Ablation of Thyroid Remnants in Patients with Graves’ Orbitopathy	27
The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease	27
Primary Hyperparathyroidism: Defining the Appropriate Preoperative Imaging Algorithm	27
Is ¹⁸F-FDG PET/CT Effective in Identifying True Residual Disease After Treatment of Pediatric PTLD?	27
Diagnostic Accuracy of⁶⁸Ga-FAPI Versus¹⁸F-FDG PET in Patients with Various Malignancies	27
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer	27
Infection Imaging: Focus on New Tracers?	26
Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, ¹⁸F-FMISO PET, and ¹⁸F-FLT PET in Relation to Contrast Enhancement in N	26
Superior Tumor Detection for⁶⁸Ga-FAPI-46 Versus¹⁸F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma	26
⁶⁸Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with¹⁸F-FDG	26
Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease	26
Impact of ¹⁸F-FET PET/MRI on Clinical Management of Brain Tumor Patients	26
State of the Art: Precision Surgery Guided by Intraoperative Molecular Imaging	25
Hot Spot Imaging in Cardiovascular Diseases: An Information Statement from SNMMI, ASNC, and EANM	25
Whole-Body PET Imaging: A Catalyst for Whole-Person Research?	25
In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using¹¹C-CHDI-180R PET in a Nonhuman Primate Model of Huntington Disease	25
Synthesis of⁶⁴Cu-,⁵⁵Co-, and⁶⁸Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macroc	25
Could FAP-Targeted Molecular Imaging Replace¹⁸F-FDG for Standard-of-Care Oncologic PET?	25
Cerenkov Luminescence Imaging in Prostate Cancer: Not the Only Light That Shines	25
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma	25
Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2—Technical)	24
Preclinical Evaluation of²²⁶Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy	24
Development and Preclinical Evaluation of [²¹¹At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer	24
Prostate-Specific Membrane Antigen–Targeted Imaging and Its Correlation with HOXB13 Expression	24
Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green	24
First-in-Human Total-Body PET/CT Imaging Using⁸⁹Zr-Labeled MUC5AC Antibody in a Patient with Pancreatic Adenocarcinoma	24
Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting	24
The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue,⁶⁸Ga-FAPI-46 PET Data, and Survival Data	24
Investigating Tau and Amyloid Tracer Skull Binding in Studies of Alzheimer Disease	24
Validation of an Artificial Intelligence–Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma	24
Association Between CA 15-3 and¹⁸F-FDG PET/CT Findings in Recurrent Breast Cancer Patients at a Tertiary Referral Hospital in Kenya	24
SNMMI Consensus Statement on Patient Selection and Appropriate Use of¹⁷⁷Lu-PSMA-617 Radionuclide Therapy	24
Theranostics in Hematooncology	24
Incidental Focal⁶⁸Ga-FAPI-46 Uptake in a Urachal Remnant: A Potential Pitfall Mimicking a Malignant Peritoneal Lesion	23
What Is Theranostics?	23
⁶⁸Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy	23
Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer ¹¹C-TASP699	23
PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study	23
CCK₂Receptor Ligand [⁶⁸Ga]Ga-DOTA-CCK-66 PET/CT Outperforms [⁶⁸Ga]Ga-DOTATOC PET/CT in a Patient with Small Cell Lung Cancer	23
One Bite from the Apple, One Bite from the Orange in the PRECISE-MDT Study	23
Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with ¹³¹I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Rem	23
Exploring Vessel Wall Biology In Vivo by Ultrasensitive Total-Body PET	23
Lesion Dosimetry for [¹⁷⁷Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer	22
Development and Validation of a¹⁸F-Flortaucipir PET Visual Stratification Method	22
Albumin-Binding and Conventional PSMA Ligands in Combination with¹⁶¹Tb: Biodistribution, Dosimetry, and Preclinical Therapy	22
Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review	22
Safety and Efficacy of 20 Cycles of [¹⁷⁷Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer	22
Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [¹⁸F]PSMA-1007 PET/CT	22
Summary: Appropriate Use Criteria for Estrogen Receptor–Targeted PET Imaging with 16α-¹⁸F-Fluoro-17β-Fluoroestradiol	22
Study of ⁸⁹Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer	22
First-in-Humans Evaluation of ¹⁸F-SMBT-1, a Novel ¹⁸F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis	21
Cyclooxygenases as Potential PET Imaging Biomarkers to Explore Neuroinflammation in Dementia	21
Interrogating Glioma-Associated Microglia and Macrophage Dynamics Under CSF-1R Therapy with Multitracer In Vivo PET/MRI	21
Predicting Outcomes of Indeterminate Bone Lesions on¹⁸F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer	21
Whole-Body PET Imaging in Humans Shows That¹¹C-PS13 Is Selective for Cyclooxygenase-1 and Can Measure the In Vivo Potency of Nonsteroidal Antiinflammatory Drugs	21
Granzyme B PET/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer	21
Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of^99mTc and¹⁸⁸Re Theranostic Agents for Prostate Cancer	21

Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?	21
Update on the Evaluation of Thyroid Nodules	21
Impact of⁶⁸Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers	21
Molecular Imaging of Systemic and Cardiac Amyloidosis: Recent Advances and Focus on the Future	20
The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [¹⁸F]MK6240 Tau PET in Target Regions	20
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities	20
In Vivo ¹⁸F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy	20
18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma	20
¹⁷⁷Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening?	20
Optimized Whole-Body PET MRI Sequence Workflow in Pediatric Hodgkin Lymphoma Patients	20
Impact of Single-Time-Point Estimates of¹⁷⁷Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles	20
Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study	20
Synergy Between Radiopharmaceutical Therapy and Immune Response: Deciphering the Underpinning Mechanisms for Future Actions	20
Diagnostic Performance and Clinical Impact of ⁶⁸Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)	20
Consensus Nomenclature for Radionuclide Therapy: Initial Recommendations from Nuclear Medicine Global Initiative	19
Safety and Efficacy ofPara-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine Tumors	19
Dose–Response Relationship in Patients with Liver Metastases from Neuroendocrine Neoplasms Undergoing Radioembolization with⁹⁰Y Glass Microspheres	19
Characterization of Effective Half-Life for Instant Single-Time-Point Dosimetry Using Machine Learning	19
MIRD Pamphlet No. 28, Part 2: Comparative Evaluation of MIRDcalc Dosimetry Software Across a Compendium of Diagnostic Radiopharmaceuticals	19
⁶⁸Ga-PSMA PET/CT–Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines	19
Clinical Experience with [²²⁵Ac]Ac-PSMA Treatment in Patients with [¹⁷⁷Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer	19
A Rare Influenza B Virus–Associated Cerebellitis Detected by¹⁸F-FDG PET/CT Imaging	19
Stacking Ensemble Learning–Based [¹⁸F]FDG PET Radiomics for Outcome Prediction in Diffuse Large B-Cell Lymphoma	19
Fast and Accurate Amyloid Brain PET Quantification Without MRI Using Deep Neural Networks	18
¹⁶¹Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of¹⁶¹Tb into the Clinic	18
High Tumor Uptake on¹⁸F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d’étude des Tumeurs Endocrines and ENDOCAN-RE	18
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study	18
Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT	18
[¹⁷⁷Lu]Lu-PSMA Therapy as an Individual Treatment Approach for Patients with High-Grade Glioma: Dosimetry Results and Critical Statement	18
Imaging Neuroinflammation in Neurodegenerative Disorders	18
Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers	18
Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?	18
Validation of the ΔSUV_maxfor Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial	18
Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial	18
⁶⁸Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the ⁶⁸Ga-FAPI PET Prospective Observational Trial	18
Sex Differences and Caffeine Impact in Adenosine-Induced Hyperemia	18
[¹⁸F]FDG PET/CT in the Initial Staging and Restaging of Soft-Tissue or Bone Sarcoma in Patients with Negative or Equivocal Findings for Metastases or Limited Recurrence on Conventional Work	18
Hybrid¹⁸F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases	17
Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental Modeling	17
Radionuclide Evaluation of Brain Death in the Post-McMath Era: Epilogue and Enigmata	17
Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine	17
Imaging Androgen Receptors in Breast Cancer with ¹⁸F-Fluoro-5α-Dihydrotestosterone PET: A Pilot Study	17
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma	17
Defining Myeloma and Advancing Treatment Options	17
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns	17
Biodistribution, Dosimetry, and Pharmacokinetics of⁶⁸Ga-CBP8: A Type I Collagen–Targeted PET Probe	17
Nuclear Medicine and Artificial Intelligence: Best Practices for Evaluation (the RELAINCE Guidelines)	17
First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [⁶⁸Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma	17
Adverse Clinical Events at the Injection Site Are Exceedingly Rare After Reported Radiopharmaceutical Extravasation in Patients Undergoing^99mTc-MDP Whole-Body Bone Scintigraphy: A 12-Year E	17
An Analysis of the Distribution of PSMA PET/CT–Positive Lymph Nodes and Their Coverage by Different Elective Nodal Radiation Volumes in Postoperative Prostate Cancer Patients	17
PSMA PET/CT and Therapy Response Evaluation in Metastatic Prostate Cancer: Is It Time to Surpass the Old Way?	17
The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.	17
Explainable Deep Learning Improves Physician Interpretation of Myocardial Perfusion Imaging	17
Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study)	17
An Intrapatient Dosimetry Comparison of¹⁷⁷Lu-rhPSMA-10.1 and¹⁷⁷Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer	17
New Developments in Myeloma Treatment and Response Assessment	17
Principles of Tracer Kinetic Analysis in Oncology, Part I: Principles and Overview of Methodology	17
RESIST-PC: U.S. Academic Foray into PSMA Theranostic Trials	16
Experience with a Perfusion-Only Screening Protocol for Evaluation of Pulmonary Embolism During the COVID-19 Pandemic Surge	16
Reply LTE, Single time point tumour dosimetry assuming normal distribution of tumour kinetics	16
Nuclear Medicine: The Essentials	16
Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is It an Either/Or Question?	16
¹⁷⁷Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine	16
Molecular Imaging Leadership in Academia and Industry	16
[¹⁸F]FET PET/MRI: An Accurate Technique for Detection of Small Functional Pituitary Tumors	16
Left Ventricular Strain from Myocardial Perfusion PET Imaging: Method Development and Comparison to 2-Dimensional Echocardiography	16
PSMA Is Not Specific to Prostate Cancer	16
HER2-Low Breast Cancer Can Be Visualized by HER2 PET	16
2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 2	16
α-Synuclein Seeding Amplification Assay: A Breakthrough in Diagnosing Parkinson Disease?	15
PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?	15
Extravasation of Diagnostic Radiopharmaceuticals: A Wolf in Sheep’s Clothing?	15
Imaging of Pheochromocytoma and Paraganglioma	15
Need for Objective Task-Based Evaluation of Image Segmentation Algorithms for Quantitative PET: A Study with ACRIN 6668/RTOG 0235 Multicenter Clinical Trial Data	15
Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery	15
Reply: Posterior Cingulate Involvement Does Not Argue Against LATE—And Who Said It Does?	15
Real-World Comparison of Cabazitaxel Versus¹⁷⁷Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer	15
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of²²³Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients	15
Impact of Radioactive Iodine Treatment on Long-Term Relative Survival in Patients with Papillary and Follicular Thyroid Cancer: A SEER-Based Study Covering Histologic Subtypes and Recurrence Risk Cate	15
Liver enzyme elevation after ¹⁷⁷Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer	15
Targeting Fibroblast Activation Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension	15
Theranostics for Meningioma on the Rise: New EANM/EANO/RANO/SNMMI Guidelines Pave the Way to Improved Patient Outcomes Using Radiolabeled Somatostatin Receptor Ligands	15
The added value of ¹⁸F-FDG PET/CT compared to ⁶⁸Ga-PSMA PET/CT in patients with castration-resistant prostate cancer	15
Impact of¹⁸F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning–Generated Biomarkers	15
The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer	15
Preclinical Characterization of the Tau PET Tracer [¹⁸F]SNFT-1: Comparison of Tau PET Tracers	15
Immuno-PET/CT Imaging of Trop2 with [¹⁸F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation	15
Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)	15
Whole-Body Parametric Imaging of ¹⁸F-FDG PET Using uEXPLORER with Reduced Scanning Time	15
⁶⁸Ga-Citrate PET of Healthy Men: Whole-Body Biodistribution Kinetics and Radiation Dose Estimates	15
Precision Medicine Clinical Trials	14
Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After⁹⁰Y Radioembolization: Potential Novel Application of	14
Leading in Urology and Pioneering in Social Media Outreach	14
From Concept to Regulatory Drug Approval: Lessons for Theranostics	14
Dosimetry of [¹⁷⁷Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis	14